Capitalization 4,002B 581B P/E ratio 2024 *
39.5x
P/E ratio 2025 * 31.2x
Enterprise value 3,109B 452B EV / Sales 2024 *
13.8x
EV / Sales 2025 * 11.3x
Free-Float
70.25%
Yield 2024 *
1.29%
Yield 2025 * 1.62%
More valuation ratios * Estimated data
Dynamic Chart
1 day-2.16%
1 week-6.97%
Current month-10.26%
1 month-8.65%
3 months+1.25%
6 months+25.14%
Current year+29.27%
More quotes
1 week
885.70
Extreme 885.7
928.00
1 month
885.70
Extreme 885.7
1 033.20
Current year
688.80
Extreme 688.8
1 033.20
1 year
525.10
Extreme 525.1
1 033.20
3 years
278.50
Extreme 278.5
1 033.20
5 years
158.03
Extreme 158.025
1 033.20
10 years
109.10
Extreme 109.1
1 033.20
More quotes
Insider TitleAgeSince
Chief Executive Officer 58 90-12-31
Director of Finance/CFO 53 98-12-31
Chief Tech/Sci/R&D Officer 57 17-12-31
Insider TitleAgeSince
Director/Board Member 62 15-03-18
Director/Board Member 59 17-03-22
Chairman 62 17-03-22
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-2.16%-6.97%+62.71%+216.13% 595B
-2.10%-8.68%+86.11%+252.19% 791B
+2.58%+3.49%-8.17%-9.03% 367B
+1.24%+0.38%+14.07%+62.39% 315B
+1.77%+4.14%+22.59%+49.09% 306B
+0.07%+5.64%-0.40%-21.25% 247B
+0.20%+0.94%+13.41%+44.03% 244B
+0.08%-2.67%+5.47%+13.82% 218B
+0.71%+0.74%+42.92%+35.48% 179B
+1.63%+1.63%-19.84%-28.07% 167B
Average -0.41%-0.57%+21.89%+61.48% 342.87B
Weighted average by Cap. -0.62%-1.90%+35.72%+107.78%
See all sector performances
Ratios2024 *2025 *
Net sales 292B 42.37B 352B 51.19B
Net income 103B 14.92B 128B 18.54B
Net Debt 17.93B 2.61B -5.76B -837M
More financial data * Estimated data
Logo Novo Nordisk A/S
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Employees
66,015
Calendar
More about the company
Date Price Change Volume
24-07-24 902.40 kr -2.16% 2,508,372
24-07-23 922.30 kr +1.46% 1,576,249
24-07-22 909.00 kr +0.32% 3,120,052
24-07-19 906.10 kr +2.15% 2,680,365
24-07-18 887.00 kr -3.48% 3,193,585

Delayed Quote Nasdaq Copenhagen, July 24, 2024 at 11:20 am EDT

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
902.40DKK
Average target price
964.56DKK
Spread / Average Target
+6.89%
Consensus
  1. Stock Market
  2. Equities
  3. NOVO B Stock